An increasing proportion of patients with heart failure receive a combination of four medications shown to improve prognosis ...
This trial assessed biomarkers and key safety parameters after initiating dapagliflozin alone versus with spironolactone in heart failure with mildly reduced or preserved ejection fraction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results